Skip to main content
SpringerLink
Log in

Wirkung des SGLT-1- und -2-Inhibitors Sotagliflozin auf die Behandlung des Diabetes mellitus Typ 1

Effect of the SGLT1 and SGLT2 inhibitor sotagliflozine on the treatment of type 1 diabetes

  • Journal Club
  • Published:
Der Diabetologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Endokrinologie, Diabetologie und klinische Ernährung, Medizinische Klinik, Kantonsspital Münsterlingen, Spitalcampus 1, 8596, Münsterlingen, Schweiz

    Vojtech Pavlicek

Authors
  1. Vojtech Pavlicek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vojtech Pavlicek.

Ethics declarations

Interessenkonflikt

V. Pavlicek gibt folgende Interessenkonflikt für diesen Artikel an: Advisory Boards für MSD, Sanofi Aventis, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Eli Lilly.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pavlicek, V. Wirkung des SGLT-1- und -2-Inhibitors Sotagliflozin auf die Behandlung des Diabetes mellitus Typ 1. Diabetologe 15, 585–586 (2019). https://doi.org/10.1007/s11428-019-0521-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-019-0521-5

Search

Navigation